Adaptive Biotechnologies’ chief commercial officer sells $831k in stock

Adaptive Biotechnologies reported Q4 2025 EPS of -$0.09 versus a -$0.18 consensus (50% positive surprise) and revenue of $71.7M, beating estimates by ~20.85%. BTIG raised its price target to $22 and TD Cowen to $21 while Piper Sandler reiterated an Overweight rating; the MRD business grew 54% YoY in Q4 and 46% for the full year. CCO Sharon Benzeno sold 63,103 shares at $13.17 for $831,066 to cover RSU tax withholding and now directly owns 272,751 shares; the stock is down 11% over the past week but up 81% over the past year and is trading above InvestingPro's fair value.

Analysis

The commercial momentum in MRD has knock-on effects that go beyond ADPT's top line: reagent and sequencer suppliers, high-throughput CAP/CLIA labs, and oncology data players are set to capture outsized incremental margin as per-test volumes scale, creating a two-tier ecosystem of asset winners (platform suppliers, outsourcing labs) versus margin-compressed incumbents that must invest to keep pace. Rapid volume growth also magnifies operational leverage risks — if throughput, reagent supply, or billing cycles slip, gross margins will re-rate faster than revenue because lab fixed costs and amortized CAPEX are front-loaded.

Key catalysts are cadence-driven and binary: quarterly volume trends and payer coverage decisions will move the valuation multiple within weeks, while durable adoption and integrated payer contracts are 12–24 month plays that justify multiple expansion. Tail risks include adverse payer rulings, a faster-than-expected competing assay that undercuts pricing, or unexpected requests for audit/recoupment — any of which can flip narrative from organic growth to margin retracement in a single quarter.

Consensus appears to price continued high single-to-double digit growth and smooth margin progression; that’s debatable. If you believe adoption is sticky, the asymmetric payoff comes from multi-year optionality as MRD becomes standard-of-care, but if you expect reimbursement/phasing issues, the nearer-term path is volatile — trade structures should therefore favor defined downside and asymmetric upside exposure rather than naked directional bets.

Key Decisions for Investors

• Tactical pullback long (ADPT): accumulate shares on a 10–15% pullback from today with a 10% stop-loss; target +35–50% over 9–12 months if sequential volumes and gross margins remain stable. R/R ~3:1 on validated growth; reduce position if payer coverage misses or unit economics weaken.
• Defined-risk options (ADPT): buy 9–12 month call spreads sized to 2–3% of portfolio (long calls and sell higher strike calls) to capture upside from multi-quarter adoption while capping premium loss to 100%. Aim for breakeven ~25–35% above entry and >2x payoff if MRD adoption accelerates.
• Pair trade (long ADPT / short ILMN): over 6–18 months, go long ADPT and short sequencing-platform exposure (ILMN) to isolate MRD commercialization upside versus platform cyclicality. Position size neutral to net portfolio beta; target a 20–30% relative spread widening, stop if spread narrows by 10%.
• Short-term sell-the-strength (ADPT): if stock gaps >15% after positive headlines, initiate a short against realized volume with a tight stop (5–8%) and plan to cover on normalization or when implied vol decays. This captures headline-driven overstretch risk with limited time exposure.